Indianapolis-based Eli Lilly and Co. (NYSE: LLY) and the Bill & Melinda Gates Foundation in Seattle have formed an agreement to provide access to COVID-19 therapeutic antibodies for low- and middle-income countries. Lilly says the agreement is part of the COVID-19 Therapeutics Accelerator initiative to reduce the burden of the virus on healthcare systems worldwide.
Lilly says the accelerator is an initiative launched by the Gates Foundation, as well as London-based Wellcome, and Mastercard (NYSE: MA) to speed the development of and access to therapies for COVID-19.
“Medicines that can help reduce the impact of COVID-19 will be an important part of the solution to this pandemic and are urgently needed by people all over the world,” said David Ricks, Lilly’s chairman and chief executive officer. “Lilly is proud to be a part of the collective global effort to help ensure equitable access to COVID-19 therapeutic options for people in low- and middle-income countries.”
You can find more information by clicking here.